1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Kwang Dong Pharmaceutical Co., Ltd.

Kwang Dong Pharmaceutical Co., Ltd.

009290.KS
Kwang Dong Pharmaceutical Co., Ltd.KR flagKorea Exchange
6,240.00
KRW
+190.00
- -
251.10BMarket Cap
Kwang Dong Pharmaceutical Co., Ltd.
009290.KS
(Korea Exchange)

Recent

price

6,240.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6,336.56
7,167.34
7,986.16
11,434.71
12,951.05
23,684.89
26,050.46
28,150.2
29,102.74
31,253.98
30,676.33
32,592.28
34,820.51
37,404.99
40,976.52
41,233.66
39,605.37
Revenue per Share
552
683.05
668
538
869
868
692
572
551
582
1,119
585
588
913
1,011
521
505.88
Basic EPS, GAAP
492.87
-12.53
-180.64
670.22
355.14
336.61
262.75
132.46
837.21
419.06
432.25
742.67
894.69
-1,158.09
-2,246.37
1,390.52
776.86
Free Cash Flow per Basic Share
51.05
50.94
51.18
59.78
71.32
79.67
80.05
80.06
80.05
81.13
78.09
100.05
99.92
101.46
100.1
97.6
- -
Dividend per Share
4,306.05
5,246.46
6,143.64
6,725.23
7,629.24
8,403.24
8,972.42
9,460.79
9,265.66
9,982.05
11,449.7
11,827.98
12,314.11
13,277.41
14,318.71
14,723.13
13,539.01
Book Value per Share
4,828.82
5,691
6,413.16
7,097.04
7,794.02
8,594.06
9,157.34
9,592.85
10,088.19
10,879.48
12,080.63
12,434.39
12,914.74
13,617.5
14,501.14
16,464.65
15,307.29
Tangible Book Value per Share
46
44
42
41
40
40
41
41
41
40
41
41
41
40
40
40
43
Basic Weighted Avg Shares
289,435
313,986
332,641
468,385
522,274
955,454
1,056,429
1,141,566
1,180,220
1,238,255
1,243,770
1,338,182
1,431,545
1,514,454
1,640,719
1,659,512
1,692,762
Sales/Revenue/Turnover
13.23
12.79
10.92
9.48
9.66
5.32
4.2
3.13
2.88
3.38
3.75
3.36
2.67
2.78
1.83
1.87
2.08
Operating Margin (%)
6,101
5,985
7,500
7,590
7,598
11,524
14,592
15,342
17,452
18,802
19,709
14,110
14,017
12,904
14,532
18,055
19,540
Depreciation Expense
25,214
29,923
27,824
22,037
35,044
35,015
28,063
23,196
22,345
23,058
45,370
24,019
24,174
36,966
40,481
20,968
21,622
Net Income, GAAP
32.72
26.49
26.01
44.76
25.95
27.42
30.59
30.79
30.01
38.38
27.56
25.6
26.43
19.68
27
31.16
31.41
Effective Tax Rate (%)
8.71
9.53
8.36
4.7
6.71
3.66
2.66
2.03
1.89
1.86
3.65
1.79
1.69
2.44
2.47
1.26
1.28
Profit Margin (%)
104,355
111,140
130,151
134,651
136,660
173,639
175,689
168,861
187,729
217,600
282,307
262,323
252,180
208,615
257,813
191,711
157,856
Working Capital
2,800
1,400
40,000
22,000
10,000
49,000
29,000
10,667
15,292
26,694
15,637
22,931
23,637
21,692
71,381
64,444
59,842
LT Debt
220,806
249,517
267,270
290,822
314,396
377,728
399,679
416,301
430,839
447,457
502,182
527,245
547,046
588,047
618,267
711,796
712,313
Total Equity
11.03
11.42
8.77
7.12
10.19
8.58
6.31
4.83
4.49
4.69
5.7
5.2
4.14
4.44
2.53
2.21
2.52
Return on Invested Capital (%)
12.39
12.97
9.93
7.07
10.34
8.52
6.27
4.96
4.83
4.91
8.31
3.92
3.7
5.38
5.44
3.05
3.12
Return on Capital (%)
13.61
14.03
11.46
8.29
12.02
10.83
7.99
6.21
5.88
5.98
10.55
5.06
4.87
7.08
7.29
3.6
3.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
222,810
238,764
241,349
LT Borrowings
56,376
54,683
51,490
LT Finance Leases
8,909
9,760
8,351
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
50
50
Market Capitalization
229,340
230,520
352,184

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
705,422
717,631
685,246
Cash, Cash Equivalents & STI
214,396
227,690
182,708
Accounts Receivable, Net
285,602
268,898
264,855
Inventories
192,544
203,574
209,155
Total Current Liabilities
499,175
525,920
527,390
Payables & Accruals
- -
- -
- -
ST Debt
222,810
238,764
241,349
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.61%
7.3%
15.13%
Free Cash Flow
21.22%
-40.65%
-162.22%
Net Income, GAAP
2.69%
-6.44%
-48.2%
Sales/Revenue/Turnover
5.72%
5.97%
1.15%
Total Cash Common Dividend
- -
- -
-2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
412,486
412,813
424,589
390,831
1,640,719
2025
377,604
425,290
444,517
412,102
1,659,512
2026
410,854
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
454
33
220
- -
1,011
2025
95
63.82
274.61
- -
521
2026
88.63
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100.1
2025
- -
- -
- -
- -
97.6
2026
- -
- -
- -
- -
- -
Similar Companies
Kyongbo Pharmaceutical Co., Ltd (214390.KS)
Viatris Inc. (VTRS)
Theratechnologies Inc. (TH.TO)
Teva Pharmaceutical Industries Limited (TEVA.TA)
Cryomass Technologies Inc. (CRYM)
BC Craft Supply Co. Ltd. (CRFT.CN)
Business
Kwang Dong Pharmaceutical Co., Ltd. (009290.KS) develops, manufactures, and markets over-the-counter (OTC) drugs, ethical drugs (ETC), health supplements, and functional beverages in South Korea. The company offers OTC products including ophthalmic solutions such as eye drops, mineral preparations, nutritious tonics, antipyretic and analgesic agents, anti-inflammatory drugs, circulatory system treatments, and vitamins; ETC drugs encompassing anti-malignant-tumor agents like Copolang, obesity treatments, appetite suppressants, neuropsychiatric solvents, digestive agents, antibiotics, and vitamins; supplements featuring low-content vitamins, minerals, and vital energy substances; and quasi-drugs alongside traditional health foods. Its prominent beverage portfolio includes Vita500 vitamin drink, Vita Gold, Red Ginseng Gold, blackberry drinks, ginger lonicerae flos beverages, corn silk tea, men's tea (oriental raisin tea), and consumer drinks such as SunKist orange soda, promoted through TV, radio, and print advertising; key OTC brands comprise Kwangdong Kyung Ok Go tonic, Kwangdong Woo Hwang Chong Shim Won stroke preparation, Kwangdong Ssangwha Tang, and eye care products like I-Talk eye drops. In the pipeline, the company advances therapies such as BST-204 for neoplasms, KD302 for neuralgia, KD103 for Alzheimer's disease, and others in preclinical stages. Kwang Dong Pharmaceutical operates primarily in the human healthcare sector, targeting consumers and healthcare professionals in South Korea with a focus on oriental medicine scientification, OTC remedies, prescription pharmaceuticals, and nutritional beverages. Founded in 1963 and headquartered at Gasan Building, 85 Seochojungang-ro, Seocho-gu, Seoul, South Korea, the company maintains about 1,032 employees and pursues R&D in cardiovascular, central nervous system, anti-infective, and ophthalmic areas. In September 2025, Kwang Dong Pharmaceutical entered an exclusive licensing agreement with Ocugen, Inc. for OCU400, a modifier gene therapy for retinitis pigmentosa (RP), securing rights in Korea with up to $7.5 million in upfront and milestone payments, potential $180 million in sales milestones over 10 years, and 25% royalties on net sales, while Ocugen handles manufacturing to bolster Kwangdong's ophthalmology portfolio alongside presbyopia and pediatric myopia pipelines. This strategic alliance enhances the company's position in advanced ophthalmic gene therapies, aiming to address approximately 7,000 RP patients in Korea pending regulatory approval. The partnership reflects Kwangdong's ongoing commitment to innovative R&D and global collaborations, building on prior achievements like the first Vitamin D injection in Korea (B.O.N.) and ERP system implementation for operational efficiency.